Journal
CLINICA CHIMICA ACTA
Volume 411, Issue 21-22, Pages 1547-1552Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2010.06.024
Keywords
Down syndrome screening; Maternal serum markers; First trimester; Adverse pregnancy outcome; Trisomy 21
Categories
Ask authors/readers for more resources
In the past two decades second-trimester maternal serum screening for Down syndrome has been the most common strategy for prenatal diagnosis of chromosomal aneuplodies Mote recently, screening for and diagnosis of chromosomal abnormalities have increasingly been performed in the first trimester With improvements and technological advances in ultrasound, it is now possible to identify many fetal anomalies at 11-13 weeks of gestation During the same period biochemical markers in maternal scrum (PAPP-A and hCG beta) combined with sonographic measurement of nuchal translucency achieve a Down syndrome detection rate of 85% with a 5% false-positive rate We describe here the potential of first-trimester markers to screen for Down syndrome as well as other adverse outcomes such as fetal loss, pre-eclampsia. intrauterine growth retardation, and preterm delivery This early consultation may be the opportunity to help counsel patients and to screen for other adverse complications during pregnancy, such as pre-eclampsia, and to manage potential adverse pregnancy outcomes (C) 2010 Elsevier BV All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available